Noscira raises capital
Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A, which owns a 62% share in the biotech company. Further investors include Corunna – a company controlled by billionaire Rosalia Mera - which holds a 5% stake. The venture capital fund Suan Biotech FCR, which is managed by Suanfarma Biotech SGECR joined public funds like FESpyme FCR in participating in the financing round. The company says the money will be used to further develop Noscira’s proprietary tideglusib (NP-12), which is currently under Phase II clinical development as a treatment for AD.